Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BCAX vs MGTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MGTX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

MGTX Overall Winner 6-Pillar Tally: BCAX 0 – 6 MGTX Matrix Metrics: BCAX 1 – 9 MGTX

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.75 (N/M Forward P/E, 0.0% operating margin), whereas MGTX carries 43.7/100 (HOLD) at $8.74 (64.1x Forward P/E, 46.3% operating margin).

  • Composite vs. Pillar Nuance: While BCAX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. MGTX 43.7/100 HOLD), MGTX captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (46.3% vs. 0.0% operating margin) and revenue trajectory (+8608.6% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile MGTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BCAX vs MGTX
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $671.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.42β · 184% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.1%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $11.85 · SMA50: $16.57
MGTX NASDAQ Head-to-Head Winner
MeiraGTx Holdings plc Ordinary Shares
Biological Products, (No Disgnostic Substances)
$8.74
-4.79% 1D
Market Cap $844.2M
TTM Revenue $398M
Forward P/E 64.1x
Beta / 30D Vol 1.66β · 69% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 33.0 Fund 58.0 Flow 70.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.7%), weak momentum, RSI 40
RSI-14: 40.5 · SMA20: $9.39 · SMA50: $10.61

6-Pillar Scorecard Institutional Category Breakdown (BCAX 0 – 6 MGTX)

Columns: Metric · BCAX · MGTX
1. Valuation Multiples MGTX
Forward P/E N/M 64.1x
Trailing P/E N/M 10.1x
PEG Ratio N/M N/M
EV / Revenue N/M 2.0x
2. Growth & Scale MGTX
Revenue Growth (YoY) +0.0% +8608.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $398M
Market Cap $671.2M $844.2M
3. Profitability & Quality MGTX
Gross Margin N/A 97.9%
Operating Margin 0.0% 46.3%
Net Profit Margin 0.0% 19.9%
Return on Equity (ROE) -54.2% 72.2%
4. Balance Sheet & Cash Flow MGTX
Cash Generation (TTM) -$163M -$28M
Cash Flow Margin N/A -7.0%
Net Cash / Leverage $81M Net Cash $51M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MGTX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 102.7% (23rd %ile) 52.9% (3rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat MGTX
OpEx & R&D Intensity N/A 51.6% of Rev ($205M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BCAX (1) vs MGTX (9)
Institutional Metric BCAX MGTX Criterion Row Edge
Market Capitalization
Scale
$671.2M $844.2M Larger Scale MGTX
Trailing P/E Ratio
Valuation
N/M 10.1x Lower Multiple MGTX
Forward P/E Ratio
Valuation
N/M 64.1x Lower Multiple MGTX
Revenue Growth (YoY)
Growth
+0.0% +8608.6% Higher Growth MGTX
Operating Margin (TTM)
Profitability
0.0% 46.3% Higher Margin MGTX
Net Profit Margin
Profitability
0.0% 19.9% Higher Margin MGTX
Return on Equity (ROE)
Capital Efficiency
-54.2% 72.2% Higher ROE MGTX
52-Week Range Position
Momentum
8% ($8–$31) 24% ($7–$15) Stronger Trend MGTX
Beta / 30D Volatility
Risk Regime
1.42β · 184% Vol 1.66β · 69% Vol Lower Realized Risk MGTX
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 43.7 / 100 (HOLD) Higher Composite BCAX
Trailing 12M Revenue (USD)
Operating Scale
N/A $398M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 97.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$163M ($81M Net Cash) -$28M ($51M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MGTX +36.08 pp
BCAX: -41.9% · MGTX: -5.82%
3M Horizon MGTX +23.79 pp
BCAX: -60.87% · MGTX: -37.08%
6M Horizon MGTX +42.44 pp
BCAX: -49.46% · MGTX: -7.02%
1Y Horizon MGTX +37.44 pp
BCAX: -31.63% · MGTX: +5.81%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs MGTX. Trailing 12-month operating profitability (BCAX 0.0% vs MGTX 46.3%) and valuation multiples (BCAX N/M vs MGTX 64.1x Forward P/E) are benchmarked directly in Pillar 4 below.

BCAX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-54.2% · N/M
MGTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$398M
Gross Margin97.9%
Op. Margin46.3%
ROE / Fwd P/E72.2% · 64.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BCAX BREAKDOWN
93d in phase · OBV ACCUMULATION
Current IV 102.7%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact BCAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MGTX BREAKDOWN
62d in phase · OBV ACCUMULATION
Current IV 52.9%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MGTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BCAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $671.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MGTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $844.2M market capitalization and 46.3% operating margin.
OpEx & R&D Reinvestment 51.6% of Rev ($205M)
90D Engineering Disclosures 0 Published

Investor FAQ BCAX vs MGTX Key Questions & Quantitative Answers

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.75 (N/M Forward P/E, 0.0% operating margin), whereas MGTX carries 43.7/100 (HOLD) at $8.74 (64.1x Forward P/E, 46.3% operating margin). Composite vs. Pillar Nuance: While BCAX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. MGTX 43.7/100 HOLD), MGTX captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (46.3% vs. 0.0% operating margin) and revenue trajectory (+8608.6% vs. +0.0% YoY). Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile MGTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MGTX leads the Growth & Scale pillar: BCAX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MGTX at +8608.6% YoY revenue growth and +0.0% YoY earnings growth on $398M TTM revenue (97.9% gross margin, 46.3% operating margin). On trailing 12-month operating scale, BCAX generates N/A in USD-normalized revenue versus $398M for MGTX. In operating R&D and SG&A reinvestment, BCAX deploys N/A (0 90-day corporate R&D disclosures) versus 51.6% of Rev ($205M) (0 disclosures) for MGTX.

MGTX screens cheaper on headline valuation multiples. BCAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MGTX trades at 64.1x Forward P/E, 10.1x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (-7.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCAX (-54.2% ROE) versus MGTX (72.2% ROE) capital efficiency.

In options market volatility and institutional positioning, BCAX carries 102.7% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 184% Vol realized risk). By comparison, MGTX carries 52.9% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.66β · 69% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.